ENYO Pharma receives Tranche 2 of its Series A investment.
ENYO Pharma has received the 10 M€ Tranche 2 of its Series A investment. The Board of Directors unanimously requested the Investors release this second Tranche of the 22 M€ Series A which closed in January 2016. This release is a response to several successfully achieved milestones, most importantly the Board decision to initiate Phase 1b in chronically infected, HBV patients. The first patients enrolment is planned for Q2 2017.
ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS
Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).
ENYO Pharma strengthens its management team to support its strategy of international growth
Lyon, November 7, 2016 – ENYO Pharma strengthens its management team to support its strategy of international growth.
J.P. Morgan 35th Annual Healthcare Conference
January 09-13, 2017
San Francisco, CA, USA
Jacky Vonderscher will be at San Francisco during the J.P. Morgan conference.
AASLD/EASL HBV Treatment Endpoints Workshop
September 08-09, 2016
Alexandria, VA, USA
AASLD and EASL possess the expertise in chronic hepatitis B and D to bridge the current knowledge gaps that regulatory and pharmaceutical industry has identified as important issues hampering development of novel therapeutic agents for chronic hepatitis B and D.
This workshop will bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.
Latest Press Release 